<DOC>
	<DOCNO>NCT01728207</DOCNO>
	<brief_summary>IMMU-114 study different dose schedule dose level order ass high dose safely tolerate . IMMU-114 administer subcutaneously ( skin ) . IMMU-114 give 1-2 time weekly 3 week follow one week rest . This consider one cycle . Treatment cycle repeat toxicity worsen disease .</brief_summary>
	<brief_title>Phase I Dose Escalation Study IMMU-114 Relapsed Refractory NHL CLL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Each patient CLL/SLL must meet follow inclusion criterion enrol study : Patients must meet diagnostic criterion CLL/SLL accord IWCLL 2008 [ 13 ] WHO Guidelines point disease course : Patients SLL : tumor biopsy immunohistochemistry diagnostic SLL blood/bone marrow immunophenotype similar CLL without lymphocytosis enlarge lymph node . Patient must relapse refractory CLL/SLL follow least one purine analogcontaining regimen ( one nonpurine analog contain regimen relative contraindication purineanalog contain therapy ) traditional option available decline . Patients prolymphocytic leukemia ( PLL ) CLL PLL transformation CLL eligible . Patients must meet IWCLL 2008 Guideline [ 13 ] criterion active disease require treatment . Each patient NHL must meet follow inclusion criterion enrol study : Patients histologically confirm Bcell NHL include marginal zone lymphoma , follicular lymphoma , mantle cell lymphoma WHO criterion . Patients must relapse refractory disease least one prior therapy traditional option available decline . All patient must meet follow inclusion criterion enrol study : Age ≥ 18 year Able understand sign write informed consent document . Able receive outpatient treatment followup treat institution . ECOG performance status 01 . Relapsed/refractory least one prior standard systemic treatment regimen , 4 . Completed prior therapy ( immunosuppressive medication , antineoplastic therapy , vaccination , immunotherapy , chemotherapy , radiotherapy , major surgery , etc ) &gt; 4 week prior first study dose medication ( alemtuzumab ≥ 6 month ) . If receiving corticosteroid , ≤ 20 mg/day prednisone equivalent unchanged Patients capable reproduction male patient partner capable reproduction must agree use effective contraceptive method course study 2 month follow completion last treatment . Females childbearing potential must negative serum βHcg pregnancy test result within 7 day first study dose . Female patient surgically sterilize &gt; 45 year old experienced menses &gt; 2 year may β Hcg pregnancy test waive . Required baseline laboratory data Platelet count ≥ 75,000/mm3 Absolute neutrophil count ( ANC ) ≥ 1500/mm3 AST/ALT ≤ 2.5 time upper limit normal ( ULN ) Creatinine total bilirubin ≤ 1.5 time ULN Patients receive antiCD20 therapy ≤ 4 week prior first study dose . Patients receive alemtuzumab ( antiCD52 ) therapy ≤ 6 month prior first study dose . Patients undergone prior allogeneic stem cell transplantation within 6 month active graft versus host disease . Patients active Richter 's syndrome ( &gt; 10 % large Bcells marrow ) . Patients designated Class III IV New York Heart Association Functional Classification . Patients history myocardial infarction stroke within last 6 month Patients transfusiondependent anemia . Patients know hypersensitivity excipient contain drug formulation . Patients history document human antiglobulin antibody . Patients active viral , bacterial systemic fungal infection require treatment . Patients know HIV hepatitis C positive . Patients history prior secondary malignancy require active systemic therapy interfere interpretation efficacy toxicity IMMU114 , limit survival 2 year . These patient discuss sponsor prior enrollment . Patients basal squamous skin carcinoma , cervical carcinoma situ biopsy , localize breast cancer require hormonal therapy localize prostate cancer ( Gleason score &lt; 5 ) require discussion . Patients active know CNS lymphoma . Patients history CNS leukemia remission eligible trial . Patients pregnant breastfeeding . Patients major surgery radiation therapy within 4 week prior first study dose . Patients must recover toxicity prior therapy radiation grade 1 less ( exclude alopecia ) . Patients substance abuse medical psychiatric condition , opinion investigator , would confound study interpretation affect patient 's ability tolerate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>CLL</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
</DOC>